Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds
Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy (ADT). Researchers at Houston’s University of Texas MD Anderson Cancer Center conducted the mice study, which appeared in the journal Nature. “A significant number of advanced prostate cancer patients

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *